Dr. Howard Smith Oncall

Vidcast:  https://www.instagram.com/p/C4gQ6IVr85r/ Women monitored with magnetic resonance imaging following initial treatment for BRCA1 positive breast cancer enjoy a 3.5-fold lower risk of mortality compared with those not monitored with such imaging.   This the conclusion of a multisite collaborative study by the Hereditary Breast Cancer Clinical Study Group.   The study reviewed the cases of 2488 women with a BRCA1 sequence variation breast cancer followed for up to 24 years.  Of that number, 1756 women had at least 1 screening MR imaging exam and a mean number of 4.7 over their follow up period.  The women in the MR group developed 241 recurrent cancers leading to 14 deaths or 5.8% mortality rate.   Among the 732 women who did not receive MR surveillance, 103 breast cancers developed leading to 21 deaths with a mortality rate of 20.3% or 3.5 fold higher mortality rate. This is the largest prospective study of MR imaging surveillance for breast cancer, but it does not specifically compare MR with othe